LEIDEN, NETHERLANDS--(Marketwire - September 03, 2008) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it has received an additional EUR 0.75 million from its co-development partner Biolex Therapeutics as part of its recently announced bridge financing. The payment by Biolex will expand OctoPlus' bridge financing to a total of EUR 6.75 million. The other participants in the bridge financing are OctoPlus' major shareholders Life Sciences Partners and SR One.
